MPLT
MapLight Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-32/100
Last price
9.69
▲ 0.41 (4.47%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
9.28
Day high
9.97
Day low
8.92
Volume
495.59K
Market cap
$538.53M
P/E (TTM)
—
52W range
8.92 – 40.43
Trailing performance
Returnvs SPY
1W
-4.53%
-6.5%
1M
-29.63%
-30.8%
3M
-74.85%
-79.4%
6M
-59.86%
-78.0%
YTD
-44.83%
-59.1%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MPLT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+8.51M
Net buying
Buy transactions
17
9.41M shares
Sell transactions
27
895.16K shares
Net transactions
+44
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
24.24M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | GILLIS JONATHAN Chief Financial Officer |
STOCK | 8.24K | $0 | Direct |
| Aug 17, 26 | KROEGER CHRISTOPHER A. M.D. Chief Executive Officer |
STOCK | 23.14K | $0 | Direct |
| Aug 17, 26 | LILLIE JAMES WOODRUFF Officer |
STOCK | 7.73K | $0 | Direct |
| Aug 17, 26 | HANSON KRISTOPHER General Counsel |
STOCK | 7.73K | $0 | Direct |
| Aug 17, 26 | KREITZER ANATOL Officer |
STOCK | 6.02K | $0 | Direct |
| Aug 17, 26 | FOFF ERIN PENNOCK Officer |
STOCK | 13.36K | $0 | Direct |
| Aug 14, 26 | CATALYST4, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.40M | $50.07M | Indirect |
| Aug 3, 26 | LILLIE JAMES WOODRUFF Officer |
SELL | 22.08K | $276.91K | Direct |
| Jul 30, 26 | CATALYST4, INC. Beneficial Owner of more than 10% of a Class of Security |
BUY | 1.21M | $15.31M | Indirect |
| Jul 28, 26 | COX TROY M Director |
BUY | 15.62K | $192.28K | Indirect |
| Jul 17, 26 | GILLIS JONATHAN Chief Financial Officer |
SELL | 36.98K | $1.37M | Direct |
| Jul 17, 26 | KROEGER CHRISTOPHER A. M.D. Chief Executive Officer |
SELL | 147.64K | $5.44M | Direct |
| Jul 17, 26 | LILLIE JAMES WOODRUFF Officer |
SELL | 18.27K | $673.64K | Direct |
| Jul 17, 26 | HANSON KRISTOPHER General Counsel |
SELL | 16.51K | $607.87K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CATALYST4, INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
FOFF ERIN PENNOCK |
Officer | 312.26K | Stock Award(Grant) |
GILLIS JONATHAN |
Chief Financial Officer | 152.48K | Stock Award(Grant) |
HANSON KRISTOPHER |
General Counsel | 153.55K | Stock Award(Grant) |
KREITZER ANATOL |
Officer | 180.93K | Stock Award(Grant) |
KROEGER CHRISTOPHER A. M.D. |
Chief Executive Officer | 1.37M | Stock Award(Grant) |
LILLIE JAMES WOODRUFF |
Officer | 210.11K | Stock Award(Grant) |
MALENKA ROBERT C. |
Director | 348.14K | Sale |
NOVO HOLDINGS A/S |
Beneficial Owner of more than 10% of a Class of Security | 3.69M | Conversion of Exercise of derivative security |
SETIA VISHWAS |
Chief Financial Officer | 356.26K | Sale |
Fundamentals
Market cap$538.53M
Enterprise value$146.66M
Revenue (TTM)—
Gross profit—
EBITDA$-242.34M
Net income$-229.83M
EPS (TTM)$-6.25
Free cash flow$-95.21M
Total cash$304.72M
Total debt$1.99M
Book value / share$7.67
Shares outstanding52.85M
Float16.05M
Short % of float10.23%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.83
PEG ratio—
Price / sales—
Price / book1.26
EV / revenue—
EV / EBITDA-0.61
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-111.55%
Return on assets-67.11%
Debt / equity0.57
Current ratio16.52
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $0 | — | — |
| Operating revenue | $0 | — | — |
| Research & development | $138.35M | — | — |
| Selling, general & admin | $30.73M | — | — |
| Total operating expense | $169.08M | — | — |
| Operating income | -$169.08M | — | — |
| Net interest income | $5.52M | — | — |
| Pre-tax income | -$161.15M | — | — |
| Net income | -$161.15M | — | — |
| Net income to common | -$161.15M | — | — |
| Basic EPS | -18.56 | -2.96 | -526.2% |
| Diluted EPS | -18.56 | -2.96 | -526.2% |
| EBIT | -$169.08M | — | — |
| EBITDA | -$168.50M | — | — |
| Basic shares | 8.68M | 26.18M | -66.8% |
| Diluted shares | 8.68M | 26.18M | -66.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $46.73M | — | — | — | — |
| Cash & short-term investments | $305.10M | — | — | — | — |
| Total current assets | $324.67M | — | — | — | — |
| Property, plant & equipment | $6.58M | — | — | — | — |
| Total assets | $479.51M | — | — | — | — |
| Total current liabilities | $16.23M | — | — | — | — |
| Total debt | $5.80M | — | — | — | — |
| Total liabilities | $21.14M | $21.72M | $20.13M | $18.52M | -2.7% |
| Retained earnings | -$360.52M | — | — | — | — |
| Shareholder equity | $458.37M | $115.19M | $71.28M | $20.87M | +297.9% |
| Working capital | $308.44M | — | — | — | — |
| Net tangible assets | $458.37M | $115.19M | $71.28M | $20.87M | +297.9% |
| Shares issued | 44.02M | — | — | — | — |
| Line item | 2025 | YoY |
|---|---|---|
| Net income | -$161.15M | |
| Depreciation & amortisation | $578.00K | |
| Stock-based compensation | $36.01M | |
| Change in working capital | -$12.84M | |
| Operating cash flow | -$138.14M | |
| Capital expenditure | -$473.00K | |
| Investing cash flow | -$323.21M | |
| Financing cash flow | $469.82M | |
| Free cash flow | -$138.61M | |
| End cash position | $46.94M |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $53.44M | $53.68M | $64.62M | $27.09M | $26.85M | -0.5% |
| Selling, general & admin | $10.11M | $10.82M | $18.75M | $4.40M | — | -6.5% |
| Total operating expense | $63.55M | $64.50M | $83.38M | $31.50M | $30.66M | -1.5% |
| Operating income | -$63.55M | -$64.50M | -$83.38M | -$31.50M | -$30.66M | +1.5% |
| Net interest income | $2.35M | $2.47M | $2.47M | $1.55M | — | -5.0% |
| Pre-tax income | -$60.19M | -$60.67M | -$79.55M | -$29.42M | -$29.84M | +0.8% |
| Net income | -$60.19M | -$60.67M | -$79.55M | -$29.42M | -$29.84M | +0.8% |
| Net income to common | -$60.19M | -$60.67M | -$79.55M | -$29.42M | -$29.84M | +0.8% |
| Basic EPS | -1.32 | -1.34 | -2.47 | -0.71 | -0.72 | +1.6% |
| Diluted EPS | -1.32 | -1.34 | -2.47 | -0.71 | -0.72 | +1.6% |
| EBIT | -$63.55M | -$64.50M | -$83.38M | -$31.50M | -$30.66M | +1.5% |
| EBITDA | -$63.40M | -$64.34M | -$83.24M | -$31.36M | -$30.53M | +1.5% |
| Basic shares | 45.43M | 45.21M | 32.15M | 41.43M | 41.43M | +0.5% |
| Diluted shares | 45.43M | 45.21M | 32.15M | 41.43M | 41.43M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $71.63M | $55.71M | $46.73M | $64.15M | — | +28.6% |
| Cash & short-term investments | $304.73M | $310.11M | $305.10M | $227.17M | — | -1.7% |
| Total current assets | $318.79M | $327.23M | $324.67M | $245.31M | — | -2.6% |
| Property, plant & equipment | $2.50M | $6.23M | $6.58M | $6.57M | — | -59.9% |
| Total assets | $368.35M | $418.79M | $479.51M | $257.22M | — | -12.0% |
| Total current liabilities | $19.29M | $14.28M | $16.23M | $18.56M | — | +35.1% |
| Total debt | $1.99M | $5.59M | $5.80M | $6.01M | — | -64.5% |
| Total liabilities | $20.05M | $18.95M | $21.14M | $23.71M | $20.36M | +5.8% |
| Retained earnings | -$481.38M | -$421.19M | -$360.52M | -$280.97M | — | -14.3% |
| Shareholder equity | $348.30M | $399.83M | $458.37M | $233.52M | $63.76M | -12.9% |
| Working capital | $299.49M | $312.94M | $308.44M | $226.74M | — | -4.3% |
| Net tangible assets | $348.30M | $399.83M | $458.37M | $233.52M | $63.76M | -12.9% |
| Shares issued | 45.44M | 45.21M | 44.02M | 41.43M | — | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$60.19M | -$60.67M | -$79.55M | -$29.42M | -$29.84M | +0.8% |
| Depreciation & amortisation | $147.00K | $162.00K | $140.00K | $136.00K | — | -9.3% |
| Stock-based compensation | $8.63M | $9.64M | $35.52M | $125.00K | — | -10.5% |
| Change in working capital | $7.33M | $273.00K | -$1.72M | -$2.39M | -$5.18M | +2,585.3% |
| Operating cash flow | -$44.87M | -$51.18M | -$46.83M | -$31.79M | — | +12.3% |
| Capital expenditure | -$22.00K | -$24.00K | -$376.00K | -$31.00K | — | +8.3% |
| Investing cash flow | $60.70M | $67.01M | -$242.55M | -$135.59M | — | -9.4% |
| Financing cash flow | $92.00K | -$6.85M | $271.96M | $198.06M | — | +101.3% |
| Free cash flow | -$44.89M | -$51.20M | -$47.20M | -$31.82M | — | +12.3% |
| End cash position | $71.84M | $55.91M | $46.94M | $64.35M | — | +28.5% |
Options analytics
Put / call volume
7.45
Put-heavy session
Put / call open interest
0.37
Positioning, not flow
Max pain
15.00
+54.8% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+193.0%
Puts bid over calls
Call volume
11
Contracts, this expiry
Put volume
82
Contracts, this expiry
Heaviest call OI
30.00
201 contracts
Heaviest put OI
7.50
90 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.31 | -1.32 | -1.0% |
| Mar 2026 | -1.09 | -1.34 | -22.9% |
| Dec 2025 | -0.83 | -2.47 | -197.6% |
| Sep 2025 | -1.73 | -37.18 | -2,055.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.17 | 8 | $0 | 0.0% |
| Next quarter | -1.06 | 8 | $0 | 0.0% |
| Current year | -4.70 | 7 | $0 | 0.0% |
| Next year | -3.42 | 10 | $15.38M | 0.0% |
Analyst targets & ownership
Mean target$26.54
High target$43.00
Low target$13.00
Implied upside173.87%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy1 / 11
Hold3
Sell / Strong sell0 / 0
Held by insiders52.28%
Held by institutions48.65%
Institutions holding148
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.12
-4.24% from price
SMA 20
11.12
-12.83% from price
SMA 50
11.98
-19.14% from price
SMA 100
21.81
-55.57% from price
SMA 200
21.40
-54.73% from price
EMA 12
10.29
-5.86% from price
EMA 26
11.49
-15.70% from price
EMA 50
14.24
-31.95% from price
RSI (14)
30.9
Neutral
MACD (12,26,9)
-1.20
Hist 0.05
ATR (14)
0.65
6.71% of price
Realised vol 30D
58.5%
Annualised
Bollinger upper
13.76
20, 2σ
Bollinger lower
8.47
20, 2σ
50 / 200 cross
Death
11.98 vs 21.40
Trend bias
Below 200
-54.73%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.84
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
58.5%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-76.7%
Peak to trough
Max drawdown 5Y
-76.7%
Peak to trough
ATR 14
0.65
6.71% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
3.30M
Prior 3.24M
Change vs prior
+1.9%
Shorts adding
% of float
10.23%
Elevated
% of shares out
5.93%
Against total outstanding
Days to cover
5.6
Crowded exit
Float
16.05M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Guggenheim | INITIATED | — | Neutral |
| Aug 31, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 10, 26 | UBS | DOWNGRADE | Buy | Neutral |
| Jul 28, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 28, 26 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Jul 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 25, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 21, 26 | UBS | MAINTAINED | Buy | Buy |
| Jul 21, 26 | BMO Capital | INITIATED | — | Outperform |
| Jul 10, 26 | Needham | MAINTAINED | Buy | Buy |
| Jun 25, 26 | Raymond James | INITIATED | — | Strong Buy |
| Jun 23, 26 | Craig-Hallum | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-1/A · 2026-09-18
Offering Registrations
S-1 · 2026-09-09
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-27
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-22
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-14
Headlines
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
GlobeNewswire · 1d ago
Guggenheim Initiates MapLight Therapeutics at Neutral
MT Newswires · 1d ago
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?
Investor's Business Daily · 28d ago
MapLight Therapeutics to Participate in Upcoming Investor Conference
GlobeNewswire · 28d ago
AstraZeneca scores in lung cancer; Sandoz inks a China deal
BioPharma Dive · 50d ago
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 55d ago
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · 55d ago
Sector Update: Healthcare Stocks Softer in Afternoon Trading
MT Newswires · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.